{"id":27841,"date":"2025-10-14T16:59:22","date_gmt":"2025-10-14T23:59:22","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27841"},"modified":"2025-10-14T17:00:24","modified_gmt":"2025-10-15T00:00:24","slug":"ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/","title":{"rendered":"IgIV para la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN)"},"content":{"rendered":"<p>Los proveedores de atenci\u00f3n m\u00e9dica a veces recomiendan <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">IgIV<\/a> tratamiento cuando el tratamiento de primera l\u00ednea, como la fototerapia, es insuficiente para los reci\u00e9n nacidos con enfermedad hemol\u00edtica isoinmune (HDN).&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-cae9c8a05a97ae180a30ab7c2c1f163c\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga autorizaci\u00f3n previa para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>La enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido es una afecci\u00f3n potencialmente mortal que se desarrolla cuando existe una incompatibilidad de grupo sangu\u00edneo entre la madre y el reci\u00e9n nacido. Esta incompatibilidad provoca la r\u00e1pida destrucci\u00f3n de los gl\u00f3bulos rojos del beb\u00e9 (hem\u00f3lisis), lo que provoca ictericia poco despu\u00e9s del nacimiento.&nbsp;<\/p>\n\n\n\n<p>La fototerapia es el tratamiento de primera l\u00ednea. Cuando no logra controlar la EHRN isoinmune en casos graves, se considera la exanguinotransfusi\u00f3n (ETE) como tratamiento de segunda l\u00ednea. Sin embargo, el tratamiento con ETE conlleva riesgos significativos para los reci\u00e9n nacidos, y para evitarlos, la terapia con IgIV suele considerarse como terapia complementaria.&nbsp;<\/p>\n\n\n\n<p>De hecho, las investigaciones han demostrado que <a href=\"https:\/\/www.dovepress.com\/immunoglobulin-transfusion-in-hemolytic-disease-of-the-newborn-place-i-peer-reviewed-fulltext-article-IJCTM#ref15\">La terapia con IgIV es segura y eficaz<\/a> Para pacientes con HDN isoinmune, ya que reduce la necesidad de procedimientos m\u00e1s invasivos y riesgosos como la BET. Contin\u00fae leyendo para saber qu\u00e9 es la HDN isoinmune. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/hemolytic-disease-of-the-newborn-causes-symptoms-treatment-and-prevention\/\">enfermedad hemol\u00edtica del reci\u00e9n nacido<\/a> (HDN) es y c\u00f3mo la IgIV puede ayudar a los reci\u00e9n nacidos.&nbsp;&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#Isoimmune_Hemolytic_Disease_of_the_Newborn_HDN_Overview\" >Enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN): descripci\u00f3n general<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#Common_Symptoms_of_Isoimmune_HDN\" >S\u00edntomas comunes de la HDN isoinmune<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#IVIG_and_Isoimmune_Hemolytic_Disease_of_the_Newborn_HDN\" >IgIV y enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#How_IVIG_Works_in_Isoimmune_Hemolytic_Disease_of_the_Newborn\" >C\u00f3mo funciona la IgIV en la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#Recommended_Dosage_of_IVIG_for_Isoimmune_Hemolytic_Disease_of_the_Newborn\" >Dosis recomendada de IgIV para la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#Reported_Adverse_Effects_of_IVIG\" >Efectos adversos notificados de la IgIV<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#Key_Takeaway\" >Conclusi\u00f3n clave<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Isoimmune_Hemolytic_Disease_of_the_Newborn_HDN_Overview\"><\/span>Enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN): descripci\u00f3n general<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN) es una afecci\u00f3n inmunomediada en reci\u00e9n nacidos. Esta afecci\u00f3n suele presentarse cuando la madre y el beb\u00e9 tienen diferentes grupos sangu\u00edneos (A, B, AB u O) y factores Rh (positivos o negativos).&nbsp;&nbsp;<\/p>\n\n\n\n<p>En la mayor\u00eda de los casos, la HDN se desencadena por una incompatibilidad del factor Rh. El factor Rh es una prote\u00edna (ant\u00edgeno D) presente en los gl\u00f3bulos rojos (GR).&nbsp;<\/p>\n\n\n\n<p>Cuando una madre con sangre Rh negativa (sin prote\u00edna Rh) tiene un beb\u00e9 con tipo de sangre Rh positiva (heredado del padre), el sistema inmunol\u00f3gico de la madre ve los gl\u00f3bulos rojos del beb\u00e9 como \u201cextra\u00f1os\u201d y produce anticuerpos contra ellos.&nbsp;<\/p>\n\n\n\n<p>Estos anticuerpos atraviesan la placenta durante el embarazo y atacan los gl\u00f3bulos rojos Rh positivo del beb\u00e9. A medida que los anticuerpos destruyen los gl\u00f3bulos rojos, el beb\u00e9 enferma. Esto se denomina eritroblastosis fetal durante el embarazo. Una vez que nace el beb\u00e9, se denomina enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN).<\/p>\n\n\n\n<p>Poco despu\u00e9s del nacimiento, los reci\u00e9n nacidos muestran s\u00edntomas de anemia e ictericia, como coloraci\u00f3n amarillenta de la piel y los ojos debido al alto nivel de bilirrubina (una sustancia amarilla que se libera durante la destrucci\u00f3n de los gl\u00f3bulos rojos).&nbsp;<\/p>\n\n\n\n<p>Como el h\u00edgado del reci\u00e9n nacido a\u00fan es inmaduro y no puede procesar ni eliminar r\u00e1pidamente el exceso de bilirrubina, \u00e9sta comienza a acumularse en el torrente sangu\u00edneo del beb\u00e9, lo que provoca s\u00edntomas de anemia e ictericia.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Common_Symptoms_of_Isoimmune_HDN\"><\/span>S\u00edntomas comunes de la HDN isoinmune<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los s\u00edntomas de la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN) pueden variar entre beb\u00e9s. Algunos s\u00edntomas comunes que puede presentar su reci\u00e9n nacido despu\u00e9s del nacimiento incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Piel p\u00e1lida e ictericia (coloraci\u00f3n amarillenta de la piel, los ojos y el cord\u00f3n umbilical) debido a anemia<\/li>\n\n\n\n<li>Agrandamiento del h\u00edgado y del bazo<\/li>\n\n\n\n<li>Letargo<\/li>\n\n\n\n<li>Frecuencia card\u00edaca r\u00e1pida<\/li>\n\n\n\n<li>Hidropes\u00eda fetal (hinchaz\u00f3n grave de todo el cuerpo)<\/li>\n\n\n\n<li><a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/25014-kernicterus\">Kern\u00edcterus<\/a> (da\u00f1o cerebral debido a la alta acumulaci\u00f3n de bilirrubina en la sangre)<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-c3f8803c373a456c5708943597e391c1\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tConsulte a un especialista en IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">M\u00e1s informaci\u00f3n<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IVIG_and_Isoimmune_Hemolytic_Disease_of_the_Newborn_HDN\"><\/span>IgIV y enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"246\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom.jpg\" alt=\"A mother holding her newborn baby\" class=\"wp-image-27844\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-300x176.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-18x12.jpg 18w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-86x50.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-167x98.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-280x164.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-mom-370x217.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>La Gu\u00eda de pr\u00e1ctica cl\u00ednica de 2022 de la Academia Estadounidense de Pediatr\u00eda (AAP) recomienda que la IgIV solo se utilice en casos selectivos y graves de HDN isoinmune, especialmente cuando:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>La bilirrubina s\u00e9rica total (BST) contin\u00faa aumentando a pesar del uso de fototerapia intensiva.\u00a0<\/li>\n\n\n\n<li>Los niveles de bilirrubina (2 \u2013 3 mg\/dl) est\u00e1n cerca del punto en el que se necesitar\u00eda una transfusi\u00f3n de intercambio de sangre.<\/li>\n\n\n\n<li>La transfusi\u00f3n de intercambio de sangre es riesgosa para el beb\u00e9 o no est\u00e1 disponible.<\/li>\n<\/ul>\n\n\n\n<p>Los art\u00edculos de observaci\u00f3n y revisi\u00f3n informan que agregar IgIV a la fototerapia intensiva en la HDN mediada por anticuerpos (Rh o ABO significativo) puede <a href=\"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/496\">aumento lento de la bilirrubina<\/a> y<strong> <\/strong><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2531137924000725?via%3Dihub\">puede disminuir la necesidad de exanguinotransfusi\u00f3n<\/a> en lactantes seleccionados.&nbsp;<\/p>\n\n\n\n<p>De manera similar, anteriormente <a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Pediatrics.&amp;title=A%20decline%20in%20the%20frequency%20of%20neonatal%20exchange%20transfusions%20and%20its%20effect%20on%20exchange-related%20morbidity%20and%20mortality&amp;author=LA%20Steiner&amp;author=MJ%20Bizzarro&amp;author=RA%20Ehrenkranz&amp;author=PG%20Gallagher&amp;volume=120&amp;publication_year=2007&amp;pages=27-32&amp;pmid=17606558&amp;doi=10.1542\/peds.2006-2910&amp;\">ensayos controlados aleatorios<\/a> demostr\u00f3 que la IgIV es eficaz en el tratamiento de neonatos con ictericia hemol\u00edtica y reduce significativamente la necesidad de exanguinotransfusiones. Asimismo, en un <a href=\"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/NPM-230070\">serie de casos<\/a> De 11 reci\u00e9n nacidos con enfermedad hemol\u00edtica isoinmune (HDN), cuando fueron tratados con 3 a 4 dosis de IgIV, los niveles de bilirrubina cayeron por debajo de los umbrales de transfusi\u00f3n de sangre en todos los casos.<\/p>\n\n\n\n<p>Adem\u00e1s, una <a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/09732179231151761\">Estudio de cohorte retrospectivo de 2023<\/a> Tambi\u00e9n se informaron los posibles beneficios de la IgIV para reducir la necesidad de exanguinotransfusi\u00f3n en la HDN isoinmune. Sin embargo, la evidencia general de alta calidad es imprecisa.&nbsp;<\/p>\n\n\n\n<p>La corriente <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18170\">pautas<\/a> Aconsejo usar IgIV solo en casos selectivos de HDN isoinmune. Por ejemplo, una <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35415922\/\">panel internacional<\/a> sugiri\u00f3 que la IgIV no debe usarse rutinariamente para tratar la HDN mediada por Rh o ABO, sino que solo debe considerarse cuando no se puede realizar f\u00e1cilmente una transfusi\u00f3n de intercambio de sangre.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_IVIG_Works_in_Isoimmune_Hemolytic_Disease_of_the_Newborn\"><\/span>C\u00f3mo funciona la IgIV en la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido\u00a0<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El mecanismo de acci\u00f3n exacto de la IgIV en la HDN isoinmune no est\u00e1 claro, pero los estudios de investigaci\u00f3n demuestran que <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18170\">La IgIV bloquea los macr\u00f3fagos<\/a> (un tipo de c\u00e9lula inmune involucrada en la destrucci\u00f3n de los gl\u00f3bulos rojos del beb\u00e9).&nbsp;<\/p>\n\n\n\n<p>Los reci\u00e9n nacidos con enfermedad hemol\u00edtica isoinmune tienen gl\u00f3bulos rojos recubiertos con los anticuerpos de la madre. Las c\u00e9lulas inmunitarias del beb\u00e9 (es decir, los macr\u00f3fagos) reconocen y destruyen estos gl\u00f3bulos rojos recubiertos de anticuerpos, lo que resulta en niveles bajos de gl\u00f3bulos rojos (anemia) y niveles altos de bilirrubina (ictericia).&nbsp;<\/p>\n\n\n\n<p>La IgIV act\u00faa interfiriendo en este proceso. Los anticuerpos proporcionados por el tratamiento con IgIV se unen a los receptores de los macr\u00f3fagos e impiden que ataquen los gl\u00f3bulos rojos recubiertos de anticuerpos del beb\u00e9.&nbsp;<\/p>\n\n\n\n<p>Al hacer esto, la IgIV retarda la descomposici\u00f3n de los gl\u00f3bulos rojos del beb\u00e9, reduce los niveles de bilirrubina y disminuye el riesgo de complicaciones graves.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recommended_Dosage_of_IVIG_for_Isoimmune_Hemolytic_Disease_of_the_Newborn\"><\/span>Dosis recomendada de IgIV para la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido\u00a0<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Seg\u00fan la Gu\u00eda de pr\u00e1ctica cl\u00ednica de la AAP 2022 y la Sociedad Canadiense de Pediatr\u00eda, la dosis recomendada de IgIV para la HDN isoinmune es de 0,5 a 1 g\/kg administrada durante 2 horas cuando los niveles s\u00e9ricos totales de bilirrubina aumentan a pesar de la fototerapia intensiva o si los niveles son 2 a 3 mg\/dl superiores al nivel de intercambio.&nbsp;<\/p>\n\n\n\n<p>A<strong> <\/strong>La segunda dosis de IgIV se puede administrar 12 horas despu\u00e9s si es necesario.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reported_Adverse_Effects_of_IVIG\"><\/span>Efectos adversos notificados de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El tratamiento con IgIV suele tolerarse bien. Sin embargo, en los reci\u00e9n nacidos, la seguridad es fundamental y la importancia de su uso es fundamental. Algunos estudios previos informaron que la IgIV puede aumentar el riesgo de enterocolitis necrosante (ECN).<strong>&nbsp;<\/strong><\/p>\n\n\n\n<p>Otros posibles efectos adversos notificados en <a href=\"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/496\">serie de casos neonatales<\/a> son trombosis, anafilaxia, cambios de l\u00edquidos e hipoglucemia.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-0f5cf51ab37c6541ada8710374a5b576\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Takeaway\"><\/span>Conclusi\u00f3n clave<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La mayor\u00eda de los beb\u00e9s con enfermedad hemol\u00edtica isoinmune (EHRN) mejoran solo con fototerapia. La IgIV solo se considera en casos seleccionados y graves de enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido, cuando la fototerapia no es suficiente y la exanguinotransfusi\u00f3n conlleva mayores riesgos.<\/p>","protected":false},"excerpt":{"rendered":"<p>Los profesionales de la salud a veces recomiendan el tratamiento con IgIV cuando el tratamiento de primera l\u00ednea, como la fototerapia, resulta insuficiente para los reci\u00e9n nacidos con enfermedad hemol\u00edtica isoinmune (EHRN). La enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido es una afecci\u00f3n potencialmente mortal que se desarrolla cuando existe una incompatibilidad de grupo sangu\u00edneo entre la madre y el reci\u00e9n nacido.<\/p>","protected":false},"author":25,"featured_media":27842,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[31],"class_list":["post-27841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-mark-alfonso"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn what isoimmune hemolytic disease of the newborn (HDN) is and how IVIG can help newborns with this condition.\u00a0\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn what isoimmune hemolytic disease of the newborn (HDN) is and how IVIG can help newborns with this condition.\u00a0\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T23:59:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T00:00:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"895\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/\"},\"author\":{\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\"},\"headline\":\"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN)\",\"datePublished\":\"2025-10-14T23:59:22+00:00\",\"dateModified\":\"2025-10-15T00:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/\"},\"wordCount\":1018,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/baby-hospital.jpg\",\"keywords\":[\"Dr. Mark Alfonso\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/\",\"name\":\"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/baby-hospital.jpg\",\"datePublished\":\"2025-10-14T23:59:22+00:00\",\"dateModified\":\"2025-10-15T00:00:24+00:00\",\"description\":\"Learn what isoimmune hemolytic disease of the newborn (HDN) is and how IVIG can help newborns with this condition.\u00a0\u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/baby-hospital.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/baby-hospital.jpg\",\"width\":1280,\"height\":895,\"caption\":\"A newborn in the hospital with isoimmune hemolytic disease of the newborn (HDN)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\",\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"caption\":\"Dr. Mark Alfonso, PharmD, BCMTMS\"},\"description\":\"Dr. Mark Alfonso, PharmD was born and raised in Pueblo, CO. He received his pharmacy degree from the University of Colorado School of Pharmacy at the Anschutz Medical Campus in 2010. He was board certified in medication therapy management in 2022. The most rewarding part of his job is helping to answer patient questions and concerns. His areas of expertise are community pharmacy and medication therapy management. In his free time, he enjoys reading and running.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/mark-alfonso\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Aprenda qu\u00e9 es la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (HDN) y c\u00f3mo la IgIV puede ayudar a los reci\u00e9n nacidos con esta afecci\u00f3n.\u00a0\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN) - AmeriPharma\u00ae Specialty Care","og_description":"Learn what isoimmune hemolytic disease of the newborn (HDN) is and how IVIG can help newborns with this condition.\u00a0\u00a0","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2025-10-14T23:59:22+00:00","article_modified_time":"2025-10-15T00:00:24+00:00","og_image":[{"width":1280,"height":895,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg","type":"image\/jpeg"}],"author":"Dr. Mark Alfonso, PharmD, BCMTMS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Mark Alfonso, PharmD, BCMTMS","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/"},"author":{"name":"Dr. Mark Alfonso, PharmD, BCMTMS","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310"},"headline":"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN)","datePublished":"2025-10-14T23:59:22+00:00","dateModified":"2025-10-15T00:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/"},"wordCount":1018,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg","keywords":["Dr. Mark Alfonso"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/","name":"IgIV para la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (EHRN) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg","datePublished":"2025-10-14T23:59:22+00:00","dateModified":"2025-10-15T00:00:24+00:00","description":"Aprenda qu\u00e9 es la enfermedad hemol\u00edtica isoinmune del reci\u00e9n nacido (HDN) y c\u00f3mo la IgIV puede ayudar a los reci\u00e9n nacidos con esta afecci\u00f3n.\u00a0\u00a0","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg","width":1280,"height":895,"caption":"A newborn in the hospital with isoimmune hemolytic disease of the newborn (HDN)"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-isoimmune-hemolytic-disease-of-newborn-hdn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"IVIG for Isoimmune Hemolytic Disease of the Newborn (HDN)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310","name":"Dr. Mark Alfonso, PharmD, BCMTMS","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","caption":"Dr. Mark Alfonso, PharmD, BCMTMS"},"description":"El Dr. Mark Alfonso, doctor en farmacia, naci\u00f3 y creci\u00f3 en Pueblo, Colorado. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus M\u00e9dico Anschutz, en 2010. Obtuvo su certificaci\u00f3n en gesti\u00f3n de terapias farmacol\u00f3gicas en 2022. Lo m\u00e1s gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus \u00e1reas de especializaci\u00f3n son la farmacia comunitaria y la gesti\u00f3n de terapias farmacol\u00f3gicas. En su tiempo libre, disfruta de la lectura y correr.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-300x210.jpg",300,210,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-768x537.jpg",768,537,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-1024x716.jpg",1024,716,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-600x420.jpg",600,420,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-86x60.jpg",86,60,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-167x117.jpg",167,117,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-280x196.jpg",280,196,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-370x259.jpg",370,259,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-960x671.jpg",960,671,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false]},"uagb_author_info":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"uagb_comment_info":0,"uagb_excerpt":"Healthcare providers sometimes recommend IVIG treatment when first-line treatment, like phototherapy, is insufficient for newborns with isoimmune hemolytic disease (HDN).\u00a0Isoimmune hemolytic disease of the newborn is a potentially life-threatening condition that develops when there is a blood group incompatibility between the mother and her newborn.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-300x210.jpg",300,210,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-1024x716.jpg",1024,716,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-600x420.jpg",600,420,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-86x60.jpg",86,60,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-167x117.jpg",167,117,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-280x196.jpg",280,196,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-370x259.jpg",370,259,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital-960x671.jpg",960,671,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/10\/baby-hospital.jpg",1280,895,false]},"rttpg_author":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Healthcare providers sometimes recommend IVIG treatment when first-line treatment, like phototherapy, is insufficient for newborns with isoimmune hemolytic disease (HDN).\u00a0Isoimmune hemolytic disease of the newborn is a potentially life-threatening condition that develops when there is a blood group incompatibility between the mother and her newborn.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27841"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27842"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27841"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}